Navigation Links
Former Secretary of Veterans Affairs James Peake to Join the Cellphire Board of Directors
Date:6/30/2009

Peake to provide guidance and direction regarding military needs, clinical uses and funding sources

ROCKVILLE, Md., June 30 /PRNewswire/ -- Cellphire, Inc., a biotechnology company located in Rockville, Md., announced today that former Secretary of the Department of Veterans Affairs, James Peake, MD, has joined its board of directors.

"I am excited about the potential of Thrombosomes(R) to save lives on the battlefield and in emergency rooms throughout the US. I am eager to contribute to the effort to conduct appropriate clinical trials to evaluate and ultimately field this product," said Dr. Peake.

Cellphire is committed to developing a freeze-dried platelet product, Thrombosomes(R), which could potentially be effective in stopping uncontrollable bleeding on the battlefield or in trauma. Platelets can only be stored for 5 days and cannot be provided to combat zones, although in-the-field harvesting is being performed. Cellphire's product is expected to have a 12 month shelf life and be immediately available for infusion after adding sterile water.

"We are excited about the addition of Dr. Peake to the Cellphire Board," said Cellphire President Mike Fitzpatrick. "With his incomparable experience and tireless commitment to providing the best possible care for the active duty uniformed services and veterans, we feel sure his contributions will help us achieve our goal."

Dr. Peake is a retired U.S. Army Lieutenant General; he was selected as the U.S. Army Surgeon General. After retirement from the Army he served as the Executive Vice President and Chief Operating Officer of Project Hope and most recently as the Secretary of the U.S. Department of Veterans Affairs. A native of St. Louis and graduate of the U.S. Military Academy at West Point, Peake attended medical school after serving in Vietnam with the 101st Airborne Division, where he was awarded the Silver Star and Purple Heart.

About Cellphire

Cellphire, Inc., a biotechnology company, is focused on developing stabilized cellular materials for advanced technologies in the therapeutic and diagnostic markets. Current efforts and product development are aimed toward stabilized platelets for advanced wound care, transfusion, and reagent products for clinical and research diagnostics.

For more information please visit: http://www.cellphire.com/.


'/>"/>
SOURCE Cellphire, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Human Genome Sciences Reports Positive Long-Term Data for BENLYSTA(TM) (Formerly LymphoStat-B(R)) in Patients With Active Systemic Lupus Erythematosus
2. Former EPA official calls for new environmental and consumer protection agency
3. Cliff Consulting, Inc. Adds Former Banking IT Executive Ashok Moorthy to Its Team
4. Former GE Healthcare Director, Per Foss Appointed CEO for HUNT Biosciences
5. Pepscan Achieves a Breakthrough With CLIPS Immunogen Technology: Synthetic Peptide Antigen is Able to Induce Fully Functional Antibodies Against a Formerly Intractable GPCR Target CXCR7
6. Lakewood-Amedex, Inc. Appoints William J. Robison, Former Executive Vice President of Pfizer, as Board Member
7. Former President of Sports Cardiology Consultants, LLC Christine Lawless, MD, MBA, ABCL, FACC, FACSM, Named Medical Director of CME Enterprise
8. Micromet Adds Former Head of Roche Oncology Kapil Dhingra, MD to Board of Directors
9. Former SADMERC Medical Directors Join OrthoCare Innovations as Medical and Scientific Advisory Board Members and Strategic Advisors
10. Cyntellect Appoints Former Millipore and BD Biosciences Executives to Head Up its Product Marketing Efforts
11. Cyntellect Appoints Former BD Biosciences Executive Andre Lubarsky as Director of Sales - North America
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... , June 23, 2016   EpiBiome , ... secured $1 million in debt financing from Silicon Valley ... up automation and to advance its drug development efforts, ... new facility. "SVB has been an incredible ... the services a traditional bank would provide," said Dr. ...
(Date:6/23/2016)... ... June 23, 2016 , ... STACS DNA Inc., the sample tracking software company, ... Crime Laboratory, has joined STACS DNA as a Field Application Specialist. , “I ... President and COO of STACS DNA. “In further expanding our capacity as a scientific ...
(Date:6/23/2016)... 2016 Apellis Pharmaceuticals, Inc. today announced ... of its complement C3 inhibitor, APL-2. The trials ... dose studies designed to assess the safety, tolerability, ... in healthy adult volunteers. Forty subjects ... single dose (ranging from 45 to 1,440mg) or ...
(Date:6/23/2016)... 23, 2016 Andrew ... http://doi.org/10.17925/OHR.2016.12.01.22 Published recently in ... journal from touchONCOLOGY, Andrew D Zelenetz , ... cancer care is placing an increasing burden on ... biologic therapies. With the patents on many biologics ...
Breaking Biology Technology:
(Date:6/3/2016)... , June 3, 2016 ... von Nepal hat ... Lieferung hochsicherer geprägter Kennzeichen, einschließlich Personalisierung, Registrierung ... in der Produktion und Implementierung von Identitätsmanagementlösungen. ... Ausschreibung im Januar teilgenommen, aber Decatur wurde ...
(Date:6/1/2016)... NEW YORK , June 1, 2016 ... Biometric Technology in Election Administration and Criminal Identification to ... According to a recently released TechSci Research report, " ... Sector, By Region, Competition Forecast and Opportunities, 2011 - ... $ 24.8 billion by 2021, on account of growing ...
(Date:5/12/2016)... May 12, 2016 WearablesResearch.com , a ... the overview results from the Q1 wave of its ... wave was consumers, receptivity to a program where they ... a health insurance company. "We were surprised ... says Michael LaColla , CEO of Troubadour Research, ...
Breaking Biology News(10 mins):